Welcome to the Hardcore Husky Forums. Folks who are well-known in Cyberland and not that dumb.
The tangled web of Washington DC
RaceBannon
Member, Swaye's Wigwam Posts: 107,553 
in Tug Tavern
Senator Blackburn is calling out Fauci
Sen. Marsha Blackburn told Newsmax that Dr. Anthony Fauci was more interested in coordinating a public relations campaign with Facebook CEO Mark Zuckerberg than "protecting the American people," and the doctor should step back from his position as head of the National Institute of Allergy and Infectious Diseases (NIAID) until a full investigation has been completed.
Blackburn appeared on "American Agenda," criticizing Fauci for his interest in protecting his image rather than the American people.
"The point is, his focus, was on himself," Blackburn said. "He was taking care of himself. He was running a PR campaign to craft a narrative that would protect him from criticism. And his job is to be protecting the American people from infectious diseases, and how unfortunate for the American people that he decided that he had dug this hole, typical of some of our bureaucrats, it was too deep to get out of; and so he was in cahoots with Mark Zuckerberg, Facebook, and big tech, in crafting a narrative that would make it look as if this is something that just happened."
"Dr. Fauci should just step aside on his own and say, 'until this issue is resolved, I am going to relinquish my position as head of the NIAID' that would be the appropriate step," the senator added.
And yet that name rang a bell from the HBO show on Opioids
“Every death from opioids is heartbreaking,” said Rep. Marsha Blackburn, the Tennessee Republican running for senate, in an earnest September campaign ad. Looking straight into the camera, Blackburn talked about new funding for treatment and the need to crack down on “drug makers who flood Tennessee with pills.”
In fact, Blackburn has been repeatedly criticized for taking money from the same pharmaceutical makers and distributors she alludes to in her ads—and crafting policy that benefits their bottom lines.
Blackburn has long been among the House’s top recipients of pharmaceutical funding, and the trend has continued during her Senate run: Of all the senate candidates running this year, Blackburn ranks 9th in campaign funding from pharmaceutical or health product PACs and employees, taking in nearly $200,000. The companies make and distribute a variety of drugs, including, but not limited to, opioids. Over the course of her career, Blackburn has received $46,500 from the three pharmaceutical distributors—McKesson, Cardinal Health, and AmerisourceBergen—often accused of flooding small towns across rural America with painkillers.
Muzzling the DEA
Among Blackburn’s signature pieces of legislation is the Ensuring Patient Access and Effective Drug Enforcement Act, a 2016 law that hampers the DEA’s ability to go after companies suspected of illegally distributing opioids. Blackburn maintains that the legislation, which passed with bipartisan support, was intended to ensure that those who needed medications could access them, but critics say that the law played to the interests of the pharmaceutical distributors, which lobbied heavily for its passage. After an investigation by the Washington Post and CBS’ 60 Minutes revealed the law’s shortcomings, Blackburn said that any negative effects on the DEA were “unintended consequences” that she vowed to fix.
Joe Rannazzisi, former head of DEA’s Office of Diversion Control, has a different recollection of the story: In a 2014 conference call with congressional staffers, Rannazzisi warned that the bill would make it far more difficult for the DEA to tackle the opioid crisis, he recently told the Associated Press. “For [Blackburn] to say she didn’t know, or those were unintended consequences, that’s nonsense because I told them what the consequences would be,” he reportedly said.
Swamp gonna swamp
Sen. Marsha Blackburn told Newsmax that Dr. Anthony Fauci was more interested in coordinating a public relations campaign with Facebook CEO Mark Zuckerberg than "protecting the American people," and the doctor should step back from his position as head of the National Institute of Allergy and Infectious Diseases (NIAID) until a full investigation has been completed.
Blackburn appeared on "American Agenda," criticizing Fauci for his interest in protecting his image rather than the American people.
"The point is, his focus, was on himself," Blackburn said. "He was taking care of himself. He was running a PR campaign to craft a narrative that would protect him from criticism. And his job is to be protecting the American people from infectious diseases, and how unfortunate for the American people that he decided that he had dug this hole, typical of some of our bureaucrats, it was too deep to get out of; and so he was in cahoots with Mark Zuckerberg, Facebook, and big tech, in crafting a narrative that would make it look as if this is something that just happened."
"Dr. Fauci should just step aside on his own and say, 'until this issue is resolved, I am going to relinquish my position as head of the NIAID' that would be the appropriate step," the senator added.
And yet that name rang a bell from the HBO show on Opioids
“Every death from opioids is heartbreaking,” said Rep. Marsha Blackburn, the Tennessee Republican running for senate, in an earnest September campaign ad. Looking straight into the camera, Blackburn talked about new funding for treatment and the need to crack down on “drug makers who flood Tennessee with pills.”
In fact, Blackburn has been repeatedly criticized for taking money from the same pharmaceutical makers and distributors she alludes to in her ads—and crafting policy that benefits their bottom lines.
Blackburn has long been among the House’s top recipients of pharmaceutical funding, and the trend has continued during her Senate run: Of all the senate candidates running this year, Blackburn ranks 9th in campaign funding from pharmaceutical or health product PACs and employees, taking in nearly $200,000. The companies make and distribute a variety of drugs, including, but not limited to, opioids. Over the course of her career, Blackburn has received $46,500 from the three pharmaceutical distributors—McKesson, Cardinal Health, and AmerisourceBergen—often accused of flooding small towns across rural America with painkillers.
Muzzling the DEA
Among Blackburn’s signature pieces of legislation is the Ensuring Patient Access and Effective Drug Enforcement Act, a 2016 law that hampers the DEA’s ability to go after companies suspected of illegally distributing opioids. Blackburn maintains that the legislation, which passed with bipartisan support, was intended to ensure that those who needed medications could access them, but critics say that the law played to the interests of the pharmaceutical distributors, which lobbied heavily for its passage. After an investigation by the Washington Post and CBS’ 60 Minutes revealed the law’s shortcomings, Blackburn said that any negative effects on the DEA were “unintended consequences” that she vowed to fix.
Joe Rannazzisi, former head of DEA’s Office of Diversion Control, has a different recollection of the story: In a 2014 conference call with congressional staffers, Rannazzisi warned that the bill would make it far more difficult for the DEA to tackle the opioid crisis, he recently told the Associated Press. “For [Blackburn] to say she didn’t know, or those were unintended consequences, that’s nonsense because I told them what the consequences would be,” he reportedly said.
Swamp gonna swamp
Comments
Not a happy camper